Nuclear Medicine and Biology
Volume 37, Issue 1 , Pages 35-40, January 2010

Radiosynthesis and ex vivo evaluation of (R)-(−)-2-chloro-N-[1-11C-propyl]n-propylnorapomorphine

  • Mikael Palner

      Affiliations

    • Neurobiology Research Unit, Rigshospitalet, University of Copenhagen, DK-2300, Copenhagen, Denmark
    • Center for Integrated Molecular Brain Imaging, Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author. Neurobiology Research Unit, Rigshospitalet, DK-2100 Copenhagen, Denmark. Tel.: +45 3545 6704; fax: +45 3545 6713.
  • ,
  • Patrick McCormick

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, M5T 1RB, Toronto, ON, Canada
  • ,
  • Nic Gillings

      Affiliations

    • Center for Integrated Molecular Brain Imaging, Copenhagen, Denmark
    • PET and Cyclotron Unit, Rigshospitalet, DK-2300, Copenhagen, Denmark
  • ,
  • Mikael Begtrup

      Affiliations

    • Center for Integrated Molecular Brain Imaging, Copenhagen, Denmark
    • Institute for Medicinal Chemistry, Pharmaceutical Faculty, University of Copenhagen, DK-2300, Copenhagen, Denmark
  • ,
  • Alan A. Wilson

      Affiliations

    • PET Centre, Centre for Addiction and Mental Health, M5T 1RB, Toronto, ON, Canada
  • ,
  • Gitte M. Knudsen

      Affiliations

    • Neurobiology Research Unit, Rigshospitalet, University of Copenhagen, DK-2300, Copenhagen, Denmark
    • Center for Integrated Molecular Brain Imaging, Copenhagen, Denmark

Received 13 March 2009; received in revised form 4 August 2009; accepted 23 August 2009. published online 05 October 2009.

Abstract 

Introduction

Several dopamine D2 agonist radioligands have been used with positron emission tomography (PET), including [11C-]-(−)-MNPA, [11C-]-(−)-NPA and [11C]-(+)-PHNO. These radioligands are considered particularly powerful for detection of endogenous dopamine release, but they either provide PET brain images with limited contrast or have affinity for both D2 and D3 receptors. We here present the carbon-11 radiolabeling and ex vivo evaluation of 2-Cl-(−)-NPA, a novel PET-tracer candidate with high in vitro D2/D3 selectivity.

Methods

2-Cl-[11C]-(−)-NPA and [11C]-(−)-NPA were synthesized by a two step N-acylation-reduction process using [11C]-propionyl chloride. Awake rats were injected with either tracer, via the tail vein. The rats were decapitated at various times, the brains were removed and quickly dissected, and plasma metabolites were measured. Radioligand specificity, and P-glycoprotein involvement in brain uptake, was also assessed.

Results

2-Cl-[11C]-(−)-NPA and [11C]-(−)-NPA were produced in high specific activity and purity. 2-Cl-[11C]-(−)-NPA accumulated slower in the striatum than [11C]-(−)-NPA, reaching maximum concentrations after 30 min. The maximal striatal uptake of 2-Cl-[11C]-(−)-NPA (standard uptake value 0.72±0.24) was approximately half that of [11C]-(−)-NPA (standard uptake value 1.37±0.18). Nonspecific uptake was similar for the two compounds. 2-Cl-[11C]-(−)-NPA was metabolized quickly, leaving only 17% of the parent compound in the plasma after 30 min. The specific binding of 2-Cl-[11C]-(−)-NPA was completely blocked and inhibition of P-glycoprotein did not alter the brain uptake.

Conclusion

Ex vivo experiments showed, despite a favorable D2/D3 selectivity, that 2-Cl-[11C]-(−)-NPA is inferior to [11C]-(−)-NPA as a PET tracer in rat, because of slower brain uptake and lower specific to nonspecific binding ratio.

Keywords: PET, Agonist, D2, D3, Dopamine, Apomorphine, 2-Cl-[11C]-(−)-NPA, [11C]-(−)-NPA, Radioligand, P-glycoprotein, Amphetamine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the Danish Agency for Science, Technology and Innovation; Rigshospitalet; the EC-FP6-project DiMI, LSHB-CT-2005-512146; the Centre of Addiction and Mental Health in Toronto, Canada; and the Lundbeck Foundation, Denmark. Ki determinations were generously performed by the National Institute of Mental Health's Psychoactive Drug Screening Program (NIMH PDSP), contract no. NO1MH32004.

PII: S0969-8051(09)00216-9

doi:10.1016/j.nucmedbio.2009.08.005

Nuclear Medicine and Biology
Volume 37, Issue 1 , Pages 35-40, January 2010